Loading provider…
Loading provider…
Medical Oncology Physician in Nashville, TN
NPI: 1427074210Primary Practice Location
TRISTAR SKYLINE MEDICAL CENTER
500 Hospital Dr, Madison, TN
Primary Employer
Nashville Oncology Associates, PC
tnoncology.com
HQ Phone
Get M.D. David's Phone NumberMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 116 | 256 |
| 2 | 80053Blood test, comprehensive group of blood chemicals | 114 | 535 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 112 | 537 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 95 | 385 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 94 | 279 |
Authors: Barlesi, Fabrice, Vansteenkiste, Johan, Spigel, David, Ishii, Hidenobu, Garassino, Marina, de Marinis, Filippo, Özgüroğlu, Mustafa, Szczesna, Aleksandra, Polychronis, Andreas, Uslu, Ruchan, Krzakowski, Maciej, Lee, Jong-Seok, Calabrò, Luana, Arén Frontera, Osvaldo, Ellers-Lenz, Barbara, Bajars, Marcis, Ruisi, Mary, Park, Keunchil
Journal: Lancet Oncol
Publication Date: 2018-09-24
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
Authors: Erika Hamilton
Journal: JCO Precis Oncol
Lead Sponsor: Tango Therapeutics, Inc.
Intervention / Treatment: DRUG: TNG908
Lead Sponsor: GlaxoSmithKline
Collaborators: iTeos Belgium SA
Intervention / Treatment: DRUG: Docetaxel, DRUG: Ipilimumab, DRUG: Dostarlimab, DRUG: GSK6097608, DRUG: Feladilimab, DRUG: GSK4428859A
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: M7824